glp 1 agonist cardiovascular outcomes Cardiovascular, mortality, and kidney with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Real-World Evidence for GLP-1 Receptor

Knowing how thalassemia affects red blood cells is key to managing it

Enhanced Mental Clarity If you struggle with brain fog, B12 shots can support focus, memory, and cognitive performance

Army Educational Outreach

On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]

Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression